^
Association details:
| Biomarker: | RET C634Y |
|---|---|
| Cancer: | Thyroid Gland Carcinoma |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ponatinib (AP24534) Is a Novel Potent Inhibitor of Oncogenic RET Mutants Associated With Thyroid Cancer
Excerpt:
...proliferation assays were performed by using different doses of compound on NIH3T3 cells transformed by RET/C634Y or RET/M918T mutants...At 6 days, 5 nM ponatinib strongly reduced cell proliferation driven by RET/C634Y (from 24 × 103% [95% CI = 19 × 103%–29 × 103%] to 16 × 103% [95% CI = 13 × 103%–19 × 103%]) and RET/M918T (from 30 × 103% [95% CI = 29 × 103%–31 × 103%] to 19.5 × 103% [95% CI = 17.5 × 103%–21.5 × 103%]) (P < .001).
DOI:
10.1210/jc.2012-2672
